Free tool
Stocks near their 52-week high
We cover 57 companies trading within 5% of their own 52-week high. The median market value in the group is $4.85B. Across the group, the median move over the past trading day is +0.08%. 98% of the 57 with a 200-day average trade above it. Price change over the past year runs from +10.0% to +205.5% across the middle 80 percent of the group, with a median of +61.7%. Across the group, 3 companies currently carry a tier A volume signal.
Other lists in this group
Table
57 of 3,992 companies match these filters.Clear filters
| Ticker | Company | Market cap (USD) | Size | 1Y return | Next report |
|---|---|---|---|---|---|
| LLY.DE | Eli Lilly and Company | $1.07T | Mega cap | +73.55% | Oct 29, 2026 |
| JNJ | Johnson & Johnson | $658.24B | Mega cap | +55.40% | Oct 13, 2026 |
| JNJ.DE | Johnson & Johnson | $651.71B | Mega cap | +58.93% | Oct 13, 2026 |
| 4AB.DE | AbbVie Inc. | $471.29B | Mega cap | +32.34% | Oct 29, 2026 |
| ABBV | AbbVie Inc. | $469.68B | Mega cap | +29.36% | Oct 29, 2026 |
| 6MK.DE | Merck & Co., Inc. | $379.64B | Mega cap | +91.49% | Oct 29, 2026 |
| MRK | Merck & Co., Inc. | $377.72B | Mega cap | +86.85% | Oct 29, 2026 |
| AMGN | Amgen Inc. | $238.06B | Mega cap | +56.24% | Nov 3, 2026 |
| AMG.DE | Amgen Inc. | $237.76B | Mega cap | +60.12% | Nov 3, 2026 |
| TMO | Thermo Fisher Scientific Inc. | $234.31B | Mega cap | +30.17% | Oct 21, 2026 |
| TN8.DE | Thermo Fisher Scientific Inc. | $234.00B | Mega cap | +29.67% | Oct 21, 2026 |
| TWST | Twist Bioscience Corporation | $9.41B | Mid cap | +451.89% | Nov 16, 2026 |
| IMVT | Immunovant, Inc. | $9.07B | Mid cap | +189.13% | Nov 9, 2026 |
| CRNX | Crinetics Pharmaceuticals, Inc. | $9.00B | Mid cap | +179.08% | Nov 5, 2026 |
| TXG | 10x Genomics, Inc. | $8.37B | Mid cap | +358.35% | Nov 5, 2026 |
| SRRK | Scholar Rock Holding Corporation | $7.31B | Mid cap | +74.18% | Nov 12, 2026 |
| 6869.T | Sysmex Corporation | $7.28B | Mid cap | +3.66% | Nov 4, 2026 |
| HNGE | Hinge Health, Inc. | $7.25B | Mid cap | +56.66% | Nov 3, 2026 |
| CHE | Chemed Corporation | $7.11B | Mid cap | +20.79% | Oct 27, 2026 |
| GETI-B.ST | Getinge AB (publ) | $7.01B | Mid cap | +20.89% | Oct 21, 2026 |
| CGON | CG Oncology, Inc. | $6.95B | Mid cap | +196.15% | Nov 9, 2026 |
| HLUN-A.CO | H. Lundbeck A/S | $6.40B | Mid cap | +29.71% | Nov 11, 2026 |
| TVTX | Travere Therapeutics, Inc. | $6.24B | Mid cap | +284.86% | Oct 29, 2026 |
| TFX | Teleflex Incorporated | $5.88B | Mid cap | +8.06% | Oct 29, 2026 |
| SHC | Sotera Health Company | $5.58B | Mid cap | +18.42% | Nov 3, 2026 |
| MMSI | Merit Medical Systems, Inc. | $5.44B | Mid cap | −0.28% | Oct 29, 2026 |
| ACAD | ACADIA Pharmaceuticals Inc. | $5.07B | Mid cap | +11.33% | Nov 4, 2026 |
| DYN | Dyne Therapeutics, Inc. | $4.92B | Mid cap | +93.26% | Nov 5, 2026 |
| HAE | Haemonetics Corporation | $4.85B | Mid cap | +93.71% | Nov 5, 2026 |
| ELVN | Enliven Therapeutics, Inc. | $4.46B | Mid cap | +194.32% | Nov 11, 2026 |
| CON | Concentra Group Holdings Parent, Inc. | $4.44B | Mid cap | +50.93% | Nov 5, 2026 |
| HTFL | Heartflow, Inc. | $4.26B | Mid cap | +40.79% | Nov 11, 2026 |
| ITGR | Integer Holdings Corporation | $4.25B | Mid cap | +15.84% | Oct 29, 2026 |
| ADPT | Adaptive Biotechnologies Corporation | $4.18B | Mid cap | +101.70% | Nov 4, 2026 |
| IDYA | IDEAYA Biosciences, Inc. | $4.01B | Mid cap | +66.32% | Nov 9, 2026 |
| ABCL | AbCellera Biologics Inc. | $3.97B | Mid cap | +181.38% | Nov 5, 2026 |
| RCUS | Arcus Biosciences, Inc. | $3.92B | Mid cap | +191.29% | Oct 27, 2026 |
| BBZA.DE | BB Biotech AG | $3.87B | Mid cap | +7.22% | Oct 23, 2026 |
| OGN | Organon & Co. | $3.62B | Mid cap | +50.67% | Nov 9, 2026 |
| IMNM | Immunome, Inc. | $3.34B | Mid cap | +188.94% | Nov 5, 2026 |
| AVAH | Aveanna Healthcare Holdings Inc. | $2.97B | Mid cap | +73.50% | Nov 5, 2026 |
| ATAI | AtaiBeckley Inc. | $2.74B | Mid cap | +61.71% | Nov 12, 2026 |
| AXGN | AxoGen, Inc. Common Stock | $2.68B | Mid cap | +219.58% | Oct 28, 2026 |
| PGEN | Precigen, Inc. | $2.65B | Mid cap | +61.66% | Nov 12, 2026 |
| CDNA | CareDx, Inc. | $2.64B | Mid cap | +283.45% | Nov 3, 2026 |
| PHVS | Pharvaris N.V. | $2.60B | Mid cap | +55.59% | Nov 12, 2026 |
| BV3.DE | Bavarian Nordic A/S | $2.55B | Mid cap | +15.65% | Nov 13, 2026 |
| RAPP | Rapport Therapeutics, Inc. | $2.52B | Mid cap | +250.70% | Nov 5, 2026 |
| DRW3.DE | Drägerwerk AG & Co. KGaA | $2.45B | Mid cap | +70.53% | Oct 29, 2026 |
| ATRC | AtriCure, Inc. | $2.45B | Mid cap | +29.14% | Oct 27, 2026 |
| HRMY | Harmony Biosciences Holdings, Inc. | $2.31B | Mid cap | +4.23% | Nov 3, 2026 |
| NEO | NeoGenomics, Inc. | $2.26B | Mid cap | +145.34% | Oct 27, 2026 |
| ADUS | Addus HomeCare Corporation | $2.25B | Mid cap | +4.50% | Nov 2, 2026 |
| PVLA | Palvella Therapeutics, Inc. | $2.22B | Mid cap | +173.39% | Nov 11, 2026 |
| MD | Pediatrix Medical Group, Inc. | $2.19B | Mid cap | +56.87% | Nov 2, 2026 |
| ZYME | Zymeworks Inc. | $2.10B | Mid cap | +96.28% | Nov 5, 2026 |
| 6960.T | Fukuda Denshi Co., Ltd. | $2.02B | Mid cap | +79.12% | Oct 29, 2026 |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.